FDA EIR - BCN Peptides SA - October 18, 2019

An FDA pre-approval inspection of BCN Peptides SA, an Active Pharmaceutical Ingredients (API) manufacturer in Sant Quinti De Mediona, Spain, took place from October 14 to October 18, 2019. The inspection's primary objectives were to evaluate the firm's readiness for commercial manufacturing, confirm adherence to its application for an active ingredient, and audit data integrity. This assessment was conducted under CVM Compliance Program 7368.001, ensuring compliance with current Good Manufacturing Practices (CGMPs) as mandated by section 501(a)(2)(b) of the Food Drug and Cosmetic Act.

Crucially, no formal objectionable conditions or violations were identified, and consequently, no FDA Form 483 Inspectional Observations were issued. This positive outcome resulted in an approval recommendation for the application. During discussions with management, two minor areas for voluntary enhancement were noted: clarifying batch record documentation for calibrated critical process equipment and improving the assay test method's sample preparation procedures. BCN Peptides SA agreed to implement these improvements, demonstrating a commitment to maintaining robust quality systems.